Related Experiment Video
Updated: Mar 30, 2026
08:59
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
8.9K
Spaceflight Effects on Cytochrome P450 Content in Mouse Liver
Natalia Moskaleva1, Alexander Moysa1, Svetlana Novikova1
1Institute of Biomedical Chemistry, Moscow, Russia.
Plos One
|November 13, 2015
Summary
Long-term spaceflight alters drug metabolism by changing cytochrome P450 (CYP) enzyme levels in mice. While some CYP levels normalize after return, others remain elevated, potentially affecting medication efficacy.
Area of Science:
- Space Medicine
- Pharmacology
- Biochemistry
Background:
- Long-term spaceflight poses challenges to biological systems, including drug metabolism.
- The cytochrome P450 (CYP) superfamily is crucial for drug biotransformation.
- Understanding CYP changes is vital for astronaut health and medication management.
Purpose of the Study:
- To investigate the impact of 30-day spaceflight and microgravity on hepatic CYP isoform content in mice.
- To identify specific CYP isoforms affected by spaceflight conditions.
- To assess the recovery of CYP levels post-flight.
Main Methods:
- Hepatic CYP isoform content was measured using mass spectrometry.
- Selected reaction monitoring (SRM) was employed for precise quantification.
- Comparison was made between mice exposed to spaceflight and a ground control group.
Main Results:
- Significant alterations in CYP2C29, CYP2E1, and CYP1A2 content were observed in spaceflight mice.
- CYP2C29 and CYP1A2 levels returned to control levels within seven days post-landing.
- CYP2E1 levels remained significantly elevated after the recovery period.
Conclusions:
- Spaceflight-induced changes in CYP enzymes can alter drug metabolism rates and efficacy.
- Elevated CYP2E1 post-flight suggests a prolonged impact on drug biotransformation.
- These findings highlight the need for personalized medication strategies in space medicine and during post-flight adaptation.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
335
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
335
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
256
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
158
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
158
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
296
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
296
01:19Factors Affecting Drug Biotransformation: Biological
840
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
840